This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cox, A D Articles by Der, C J Search for Related Content PubMed PubMed Citation Articles by Cox, A D Articles by Der, C J

 Previous Article  |  Next Article 

Mol Cell Biol. 1992 June; 12(6): 2606-2615

Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein.

La Jolla Cancer Research Foundation, California 92037.

ABSTRACT

While the Ras C-terminal CAAX sequence signals modification by a 15-carbon farnesyl isoprenoid, the majority of isoprenylated proteins in mammalian cells are modified instead by a 20-carbon geranylgeranyl moiety. To determine the structural and functional basis for modification of proteins by a specific isoprenoid group, we have generated chimeric Ras proteins containing C-terminal CAAX sequences (CVLL and CAIL) from geranylgeranyl-modified proteins and a chimeric Krev-1 protein containing the H-Ras C-terminal CAAX sequence (CVLS). Our results demonstrate that both oncogenic Ras transforming activity and Krev-1 antagonism of Ras transforming activity can be promoted by either farnesyl or geranylgeranyl modification. Similarly, geranylgeranyl-modified normal Ras [Ras(WT)CVLL], when overexpressed, exhibited the same level of transforming activity as the authentic farnesyl-modified normal Ras protein. Therefore, farnesyl and geranylgeranyl moieties are functionally interchangeable for these biological activities. In contrast, expression of moderate levels of geranylgeranyl-modified normal Ras inhibited the growth of untransformed NIH 3T3 cells. This growth inhibition was overcome by coexpression of the mutant protein with oncogenic Ras or Raf, but not with oncogenic Src or normal Ras. The similar growth-inhibiting activities of Ras(WT)CVLL and the previously described Ras(17N) dominant inhibitory mutant suggest that geranylgeranyl-modified normal Ras may exert its growth-inhibiting action by perturbing endogenous Ras function. These results suggest that normal Ras function may specifically require protein modification by a farnesyl, but not a geranylgeranyl, isoprenoid.

This article has been cited by other articles:

• Rowinsky, E. K. (2006). Lately, It Occurs to Me What a Long, Strange Trip It's Been for the Farnesyltransferase Inhibitors. JCO 24: 2981-2984 [Full Text]  
• Joyce, P. L., Cox, A. D. (2003). Rac1 and Rac3 Are Targets for Geranylgeranyltransferase I Inhibitor-Mediated Inhibition of Signaling, Transformation, and Membrane Ruffling. Cancer Res. 63: 7959-7967 [Abstract] [Full Text]  
• Fiordalisi, J. J., Johnson, R. L. II, Weinbaum, C. A., Sakabe, K., Chen, Z., Casey, P. J., Cox, A. D. (2003). High Affinity for Farnesyltransferase and Alternative Prenylation Contribute Individually to K-Ras4B Resistance to Farnesyltransferase Inhibitors. J. Biol. Chem. 278: 41718-41727 [Abstract] [Full Text]  
• Carey, K. D., Watson, R. T., Pessin, J. E., Stork, P. J. S. (2003). The Requirement of Specific Membrane Domains for Raf-1 Phosphorylation and Activation. J. Biol. Chem. 278: 3185-3196 [Abstract] [Full Text]  
• Solski, P. A., Helms, W., Keely, P. J., Su, L., Der, C. J. (2002). RhoA Biological Activity Is Dependent on Prenylation but Independent of Specific Isoprenoid Modification. Cell Growth Differ. 13: 363-373 [Abstract] [Full Text]  
• Lobell, R. B., Liu, D., Buser, C. A., Davide, J. P., DePuy, E., Hamilton, K., Koblan, K. S., Lee, Y., Mosser, S., Motzel, S. L., Abbruzzese, J. L., Fuchs, C. S., Rowinsky, E. K., Rubin, E. H., Sharma, S., Deutsch, P. J., Mazina, K. E., Morrison, B. W., Wildonger, L., Yao, S.-L., Kohl, N. E. (2002). Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I. Molecular Cancer Therapeutics 1: 747-758 [Abstract] [Full Text]  
• Fiordalisi, J. J., Holly, S. P., Johnson, R. L. II, Parise, L. V., Cox, A. D. (2002). A Distinct Class of Dominant Negative Ras Mutants. CYTOSOLIC GTP-BOUND Ras EFFECTOR DOMAIN MUTANTS THAT INHIBIT Ras SIGNALING AND TRANSFORMATION AND ENHANCE CELL ADHESION. J. Biol. Chem. 277: 10813-10823 [Abstract] [Full Text]  
• Lobell, R. B., Omer, C. A., Abrams, M. T., Bhimnathwala, H. G., Brucker, M. J., Buser, C. A., Davide, J. P., deSolms, S. J., Dinsmore, C. J., Ellis-Hutchings, M. S., Kral, A. M., Liu, D., Lumma, W. C., Machotka, S. V., Rands, E., Williams, T. M., Graham, S. L., Hartman, G. D., Oliff, A. I., Heimbrook, D. C., Kohl, N. E. (2001). Evaluation of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Inhibitor Combinations in Preclinical Models. Cancer Res. 61: 8758-8768 [Abstract] [Full Text]  
• Omer, C. A., Chen, Z., Diehl, R. E., Conner, M. W., Chen, H. Y., Trumbauer, M. E., Gopal-Truter, S., Seeburger, G., Bhimnathwala, H., Abrams, M. T., Davide, J. P., Ellis, M. S., Gibbs, J. B., Greenberg, I., Hamilton, K., Koblan, K. S., Kral, A. M., Liu, D., Lobell, R. B., Miller, P. J., Mosser, S. D., O’Neill, T. J., Rands, E., Schaber, M. D., Senderak, E. T., Oliff, A., Kohl, N. E. (2000). Mouse Mammary Tumor Virus-Ki-rasB Transgenic Mice Develop Mammary Carcinomas That Can Be Growth-inhibited by a Farnesyl:Protein Transferase Inhibitor. Cancer Res. 60: 2680-2688 [Abstract] [Full Text]  
• Rowinsky, E. K., Windle, J. J., Von Hoff, D. D. (1999). Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development. JCO 17: 3631-3652 [Abstract] [Full Text]  
• Du, W., Prendergast, G. C. (1999). Geranylgeranylated RhoB Mediates Suppression of Human Tumor Cell Growth by Farnesyltransferase Inhibitors. Cancer Res. 59: 5492-5496 [Abstract] [Full Text]  
• Sun, J., Blaskovich, M. A., Knowles, D., Qian, Y., Ohkanda, J., Bailey, R. D., Hamilton, A. D., Sebti, S. M. (1999). Antitumor Efficacy of a Novel Class of Non-thiol-containing Peptidomimetic Inhibitors of Farnesyltransferase and Geranylgeranyltransferase I: Combination Therapy with the Cytotoxic Agents Cisplatin, Taxol, and Gemcitabine. Cancer Res. 59: 4919-4926 [Abstract] [Full Text]  
• Du, W., Lebowitz, P. F., Prendergast, G. C. (1999). Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB. Mol. Cell. Biol. 19: 1831-1840 [Abstract] [Full Text]  
• Niv, H., Gutman, O., Henis, Y. I., Kloog, Y. (1999). Membrane Interactions of a Constitutively Active GFP-Ki-Ras 4B and Their Role in Signaling. EVIDENCE FROM LATERAL MOBILITY STUDIES. J. Biol. Chem. 274: 1606-1613 [Abstract] [Full Text]  
• De Smedt, F., Missiaen, L., Parys, J. B., Vanweyenberg, V., De Smedt, H., Erneux, C. (1997). Isoprenylated Human Brain Type I Inositol 1,4,5-Trisphosphate 5-Phosphatase Controls Ca2+ Oscillations Induced by ATP in Chinese Hamster Ovary Cells. J. Biol. Chem. 272: 17367-17375 [Abstract] [Full Text]  
• Raiteri, M., Arnaboldi, L., Mcgeady, P., Gelb, M. H., Verri, D., Tagliabue, C., Quarato, P., Ferraboschi, P., Santaniello, E., Paoletti, R., Fumagalli, R., Corsini, A. (1997). . J. Pharmacol. Exp. Ther. 281: 1144-1153 [Abstract] [Full Text]  
• Boyartchuk, V. L., Ashby, M. N., Rine, J. (1997). Modulation of Ras and a-Factor Function by Carboxyl-Terminal Proteolysis. Science 275: 1796-1800 [Abstract] [Full Text]  
• Lerner, E. C., Qian, Y., Hamilton, A. D., Sebti, S.īd M. (1995). Disruption of Oncogenic K-Ras4B Processing and Signaling by a Potent Geranylgeranyltransferase I Inhibitor. J. Biol. Chem. 270: 26770-26773 [Abstract] [Full Text]  
• Lerner, E. C., Qian, Y., Blaskovich, M. A., Fossum, R. D., Vogt, A., Sun, J., Cox, A. D., Der, C. J., Hamilton, A. D., Sebti, S.īd M. (1995). Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes. J. Biol. Chem. 270: 26802-26806 [Abstract] [Full Text]  
• Kisselev, O., Ermolaeva, M., Gautam, N. (1995). Efficient Interaction with a Receptor Requires a Specific Type of Prenyl Group on the G Protein [IMAGE] Subunit. J. Biol. Chem. 270: 25356-25358 [Abstract] [Full Text]  
• Kalman, V. K., Erdman, R. A., Maltese, W. A., Robishaw, J. D. (1995). Regions Outside of the CAAX Motif Influence the Specificity of Prenylation of G Protein [IMAGE] Subunits. J. Biol. Chem. 270: 14835-14841 [Abstract] [Full Text]  
• James, G. L., Goldstein, J. L., Brown, M. S. (1995). Polylysine and CVIM Sequences of K-RasB Dictate Specificity of Prenylation and Confer Resistance to Benzodiazepine Peptidomimetic in Vitro. J. Biol. Chem. 270: 6221-6226 [Abstract] [Full Text]  
• Vogt, A., Qian, Y., Blaskovich, M. A., Fossum, R. D., Hamilton, A. D., Sebti, S. M. (1995). A Non-peptide Mimetic of Ras-CAAX: Selective Inhibition of Farnesyltransferase and Ras Processing. J. Biol. Chem. 270: 660-664 [Abstract] [Full Text]  
• Hennekes, H, Nigg, E. (1994). The role of isoprenylation in membrane attachment of nuclear lamins. A single point mutation prevents proteolytic cleavage of the lamin A precursor and confers membrane binding properties. J. Cell Sci. 107: 1019-1029 [Abstract]  
• Kohl, N., Mosser, S., deSolms, S., Giuliani, E., Pompliano, D., Graham, S., Smith, R., Scolnick, E., Oliff, A, Gibbs, J. (1993). Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260: 1934-1937 [Abstract]  
• Allal, C., Favre, G., Couderc, B., Salicio, S., Sixou, S., Hamilton, A. D., Sebti, S. M., Lajoie-Mazenc, I., Pradines, A. (2000). RhoA Prenylation Is Required for Promotion of Cell Growth and Transformation and Cytoskeleton Organization but Not for Induction of Serum Response Element Transcription. J. Biol. Chem. 275: 31001-31008 [Abstract] [Full Text]